NeuroScanner-Rare Diseases
The Electronic Health Record (EHR) Screening System is a software solution based on artificial intelligence technologies (CDSS Neuro-Scanner-Rare Diseases). This product increases the efficiency of detecting patients with orphan diseases for further treatment.
The pre-trained CV and NLP models analyze studies, physician EHR epicrisis, and patient pedigree to predict the risk of orphan diseases in children and diagnose these diseases in newborns. The following diseases currently can be analyzed:
• Mucopolysaccharidosis type 1
• Fabry disease
• Pompe's disease
• Niemann-Pick disease type A / B (ASMD)
Technical Architecture
Technology
Tech Platform
Software Requirements Specifications Overview
Digital Transformation Domain
Project Type
Service Model
Business and Economic Impact
Industry
Project Status
Successfully Deployed in Industry
Unit Cost
$50,000
Economic Impact
AI-Driven Early Detection of Rare Genetic Disorders: Harnessing advanced artificial intelligence and machine learning algorithms, our platform significantly increases the identification rate of patients with rare genetic diseases, enabling timely intervention and personalized treatment. This breakthrough in AI-powered healthcare analytics not only improves patient outcomes but also reduces long-term healthcare costs by facilitating early diagnosis and targeted therapies. By leveraging big data, predictive modeling, and digital health transformation, businesses and medical providers benefit from optimized resource allocation, enhanced operational efficiency, and a measurable boost in economic value. Empower your organization with AI solutions that drive innovation, accelerate medical advancements, and maximize return on investment in the healthcare sector.
Social & Environmental Impact
Digital Transformation Domain
AI-Driven Social & Environmental Impact: Transforming Public Health and Service Quality
Leveraging advanced artificial intelligence technologies, our platform delivers measurable improvements in population longevity and overall well-being. AI-powered analytics and healthcare solutions enhance life expectancy by enabling early detection and personalized interventions, driving sustainable public health outcomes.
Pricing Model
Out-licensing & Milestone Payments
Standalone AI Software Product
MARKET CAPABILITY & CONSUMER GROUPS
INVESTMENT RETURN & SUSTAINABILITY
TARGET MARKET SEGMENTS
Individuals, Corporations/Legal Entities and Government Agencies/State Executive Authorities
KEY CLIENT & CUSTOMERS
PROJECTED SALES METRICS
Свердловская область Санофи ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России
Estimated Contract Value / Project Revenue: From 150 million RUB to 300 million RUB. The exact contract value will be finalized following the review and approval of the technical specifications (Statement of Work).
PRODUCT SUPPORT COSTS
Initial Deployment & Support Cost: From 6 million RUB.
Average Annual Total Cost of Ownership (TCO): From 2 million RUB.
Final Pricing Specification: The exact costs will be finalized following the review and approval of the technical specifications (Statement of Work).
INVESTMENT RETURN
Careers Anchor
Executive Roles
My Companies
